多发性骨髓瘤
癌基因
癌症研究
发病机制
化疗
抗药性
医学
疾病
生物
免疫学
癌症
病理
内科学
细胞周期
遗传学
作者
He Huang,Wenjian Guo,Ron-xin Yao
出处
期刊:Zhongguo shi yan xue ye xue za zhi
日期:2016-08-01
卷期号:24 (4): 1248-51
被引量:2
标识
DOI:10.7534/j.issn.1009-2137.2016.04.053
摘要
Multiple myeloma(MM) as one of the most common tumors of hmatologic system, is characterized by malignant proliferation of plasma cells, and the chemotherapy is the main therapeutic method. MM is an incurable disease because of drug-resistance of MM cells. Although the pathogenesis of MM remains unknown, the chromosome abnormalities exit in half of the patients, particularly the highly expressed gene C-MYC. Furthermore, plenty of clinical researches indicated a high expression level of C-MYC implied worse progression and/or poor prognosis of MM. Recently, the work exploiting the compounds targeting MYC has made substantial progress, even in the MM therapy. In this article, briefly the recent advances of the research on C-MYC proto-oncogene in multiple myeloma are reviewed.
科研通智能强力驱动
Strongly Powered by AbleSci AI